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Abstract.  Extracts  from atrial  and  ventricular  heart 
tissue of several species (chicken,  rat,  sheep,  and cow) 
are strongly mitogenic  for chicken  skeletal myoblasts, 
with the highest apparent  concentration  of biological 
activity in the atrial  extracts.  Using  several approaches 
(biological activity assay and biochemical  and  im- 
munological  analyses),  we have established that  (a) all 
cardiac  extracts contain  an  18,000-D peptide which  is 
identified as basic fibroblast growth factor (bFGF) 
since it elutes from heparin-Sepharose  columns at salt 
concentrations  >1.4 M  and  is recognized by bFGF- 
specific affinity-purified antibodies;  (b) bFGF is more 
abundant  in the atrial  extracts  in all  species so exam- 
ined;  (c) avian cardiac  tissue extracts contain  the 
highest concentration  of immunoreactive  bFGF;  and 
(d) avian ventricles  contain  a higher  relative molecular 
mass (23,000-D) bFGF-like peptide  which is absent 
from atrial  extracts.  Examination  of frozen bovine 
cardiac tissue sections by indirect  immunofluorescence 
using anti-bFGF  antibodies  shows bFGF-like reactivity 
associated with nuclei and  intercalated  discs of muscle 
fibers.  There  is substantial  accumulation  of bFGF 
around  atrial  but not ventricular  myofibers, resulting 
most likely from more extensive endomysium in the 
atria.  Blood vessels and  single,  nonmuscle,  connective 
tissue cells react strongly with the anti-bFGF  antibod- 
ies.  Higher bFGF content and pericellular  distribution 
in atrial  muscles suggest a  correlation  with increased 
regenerative  potential  in this tissue.  Distribution  within 
the myofibers is intriguing,  raising  the possibility for 
an  intimate  and continuous  involvement of bFGF-like 
components  with normal  myocardial  function. 
T 
ISSUES with extensive vascularization accumulate sub- 
stantial amounts of heparin-binding growth factors (5, 
18-20, 25). The best studied members of this category 
of growth factors are acidic and basic fibroblast growth fac- 
tors (aFGF and bFGF,  respectively) t which have 55 %  se- 
quence homology (13, 15, 20) and a similar spectrum of bio- 
logical activity, with bFGF being 30 times more potent than 
aFGF (18-20).  bFGF is a  multifunctional  peptide.  It is a 
powerful mitogen for cells of mesodermal and neuroectoder- 
mal  origin  (18-20),  a  mesoderm  inducer  (morphogen)  in 
embryonic development  (28,  41),  and  a  differentiation  in- 
ducer for some cell types (1). Because of its high affinity for 
heparin  (17),  bFGF is accumulated in heparan-sulfate-rich 
extracellular matrices; it binds to retina basement membranes 
(21) and  is  extracted  from the  extracellular  matrix  of en- 
dothelial  cells in  culture  (4).  Endothelial  cells synthesize 
bFGF in vitro (45) and may be responsible for the high bFGF 
accumulation in heavily vascularized tissues. Nevertheless, 
its precise localization  in tissues,  cellular origin,  or local 
function are still not established. It is believed that bFGF is 
involved  in  angiogenesis,  wound  repair,  and  regeneration 
(18-20). 
1. Abbreviations used in this paper: aFGF, acidic fibroblast growth factor; 
bFGF,  basic  fibroblast growth  factor;  IGF,  insulin-like growth  factor; 
TGFB,  transforming growth  factor B. 
In one type of striated muscle, skeletal muscle, bFGF has 
a dual effect; it stimulates embryonic myoblast proliferation 
(25, 26) and inhibits differentiation independently of cell di- 
vision (42). bFGF is highly mitogenic for adult skeletal mus- 
cle  stem  (satellite)  cells  (3),  is  accumulated  in  satellite 
cell-rich muscles (25), and is thus considered to participate 
in  muscle  regeneration  after injury.  Regenerating  skeletal 
muscle has high  levels of mitogenic  activity  (7).  Interest- 
ingly, physiologically occurring components such as hepa- 
rin-like substances and transforming growth factor/~ (TGF/3) 
can inhibit the action of bFGF on skeletal muscle (14), pre- 
senting a plausible model for regulation  in vivo. 
Another striated muscle, cardiac ventricular myocardium, 
is considered essentially incapable of regeneration (47). Af- 
ter birth, ventricular myocytes rapidly lose their proliferative 
potential and become terminally differentiated (47); a slug- 
gish attempt for resumption of DNA synthesis by these cells 
after tissue damage has been observed (37).  Furthermore, 
there are reports that ventricular myocytes in culture can be 
induced to resume DNA synthesis (10); this implies environ- 
mentally imposed restrictions rather than irreversible loss of 
this property.  Adult atrial  myocytes retain  their ability for 
synthesizing DNA in vivo to a considerable extent (38). Lit- 
tle  is  known  about the  molecular  mechanisms  governing 
proliferation of cardiac myocytes. As with skeletal myoblasts 
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to  stimulate  DNA  synthesis  of adult ventricular  myocytes 
(9). We have also found bFGF to stimulate proliferation of 
both atrial and ventricular  myocytes from neonates, an activ- 
ity inhibited by TGFB (21,  22).  These similarities between 
the  two muscle  types  led us  to  hypothesize  that,  as  with 
skeletal  muscle  (24,  25),  activities  present in the cardiac 
milieu could affect cardiomyocyte proliferation and differen- 
tiation and possibly  account for differences between adult 
atrial and ventricular myocytes. To investigate  this, we have 
examined the biological activity of heart extracts and quanti- 
tared bFGF-like  peptides  in  atria  and  ventricles  of avian 
(chicken) and mammalian (rat, sheep, and cow) species; in 
addition we studied the localization of bFGF-like reactivities 
in the heart.  We found differences in quantity  and distribu- 
tion of bFGF-like components between atria and ventricles 
which could have a bearing on their respective proliferative 
properties.  Furthermore, the observed intimate association 
with cardiac myofibers raises the possibility for a continuous 
involvement of bFGF-like peptides with normal cardiac myo- 
cyte properties. 
Materials and Methods 
Cell Culture 
Skeletal myoblasts from  12-d chick embryos, obtained as previously de- 
scribed  (26),  were  cultured  on  gelatin  (0.3%)-coated  dishes  in  10% 
(vol/vol)  horse  serum  (HyClone  Laboratories,  Logan,  tiT),  25  ~g/ml 
chicken  transferrin  (Cooper  Biomedical,  Inc.,  Malvern,  PA)  in  MEM 
(Gibeo Laboratories, Grand Island, NY).  Plating density was  15,000  and 
50,000 cells per well (96- and 24-well plates,  respectively). 
Rabbit fetal chondrocytes were a gift from Dr.  Friesen (University of 
Manitoba, Winnipeg, Manitoba, Canada) and were cultured as described 
(27, 44). For [3H]thymidine incorporation assays, chondrocytes were plated 
in 96-well dishes at 5,000 cells/well in 10% FCS (Flow Laboratories, Mis- 
sissanga, Ontario, Canada) and Ham's F-10 medium (Gibco Laboratories). 
24 h  after plating,  medium was  removed and replaced with Ham's F-10 
medium (Gibco Laboratories) containing 1% BSA. Extracts, growth factors, 
and column eluates were subsequently added,  followed by  1 ~tCi/weil of 
[3H]thymidine (Amersham Corp., Arlington Heights, IL). [3H]Thymidine 
incorporation was determined 20 h later as described (16). Recombinant bo- 
vine bFGF was purchased from Amersham Corp. Porcine or human TGF~ 
and TGF/~-neutralizing rabbit IgGs were purchased from R &  D Systems, 
Inc. (Minneapolis, MN), and insulin-like growth factor (IGF) I was from 
Calbiochem-Behring Corp. (San Diego, CA). All cells were maintained at 
37°C  in a humidified atmosphere of 5% CO2  in air. 
Biological  Activity of the Extracts 
Extracts to be tested for mitogenic activity were added to the cells once, at 
the time of plnting, at a final concentration of 0.1-1 mg/ml. Cells were grown 
on 96-well plates.  [3H]Thymidine was added to the cells after 20-24 h  in 
vitro at I #Cilwell. [3H]Thymidine incorporation was determined 10-12 h 
later (16). To test for differentiation-inhibiting activity, extracts were added 
to myoblast cultures (in 24-well dishes) at a final concentration of 0.5 mg/ml 
(in quadruplicate wells).  To assess differentiation, cultures were fixed in 
cold ethanol/formalin (9:1) and stained with eosin and hematoxylin (Sigma 
Chemical Co., St. Louis, MO) before determining fusion index (nuclei in- 
side myotubes/total number of nuclei); for the latter,  four representative 
fields from each well were photographed and the nuclei inside and outside 
myotubes were scored (minimum of 500 nuclei per well). 
Preparation of IIssue Extracts 
All procedures were performed at 4°C unless otherwise specified. Immedi- 
ately after dissection, heart tissue was cleared of fat and large vessels and 
either processed  immediately or frozen in liquid nitrogen and stored at 
-70°C.  For  extraction,  tissue  was  weighed,  minced  with  scissors,  and 
homogenized briefly in 2  vol (over weight) of MEM with a homogenizer 
(Polytron; Brinkmann Instruments Co., Rexdale, Ontario, Canada) at low 
setting.  Residual  tissue  was  removed  by  centrifugntion  in  a  centrifuge 
(Ultracentrifuge; Beckman Instruments, Inc., Fuilertun, CA) at 35,000 rpm 
for 40 rain at 4°C, and the supernatant was stored in sterile tubes at -70°C 
after  filtration  through  low  protein-binding  0.2-/tin  filters  (Millipore- 
Continental V~ater Systems, Bedford, MA). Protein concentration was de- 
termined using a colorimetric assay (Bradford reagent; Bio-Rad Laborato- 
ries,  Richmond, CA). 
SDS-PAGE 
The presence of bFGF in samples was assessed by standard SDS-PAGE (30) 
in 1.5-mm-thick,  15% pulyacrylamide slab gels.  Protein molecular mass 
standards (10,000-100,000 D; Bio-Rad Laboratories) as well as pure recom- 
binant bovine bFGF were included in each analysis. Silver staining of gels 
was performed as described (31). 
lmmunoblotting and Autoradiography 
Gels were transferred onto nitrocellulose membrane (0.2 ~m; Schleicher & 
Schuell, Inc., Keene, NH) by electrophoretic transfer (Transblot; Bio-Rad 
Laboratories).  After  transfer  and  blocking  of the  nonspecific  protein- 
binding sites with 1% BSA-PBS, the nitrocellulose membrane was incubated 
with 40 ng/ml of the purified anti-bFGF IgGs in wash buffer (10 mM Tris- 
HCI, pH 8, 0.15 M NaCI, 0.05 % Tween-20) overnight at 4°C. Antigen-anti- 
body complexes were visualized by incubating the membrane (8) with 0.1 
~Ci/ml of n25I-protein  A (Amersham Corp.) in wash buffer for 1 h. Auto- 
radiography was performed with X-omat film (Eastman Kodak Co., Roches- 
ter, NY) and intensifying screens at -70°C for 1-7 d. Autoradiograms were 
scanned with a laser densitometer (Ultroscan 2202; LKB Instruments, Inc., 
Gaithersburg, MD) to determine the relative intensity of the bands. 
Heparin-Sepharose Aj~inity Chromatography 
Heparin-Scpharose (Pharmacia Fine Chemicals, Uppsala, Sweden) affinity 
chromatography  was used for bFGF isolation from cardiac extracts.  Ex- 
tracts were made up to 0.6 M NaCI by adding solid NaCI and passed twice 
through heparin-Sepharose columns equilibrated in 0.6 M  NaCI,  10 mM 
Tris-HC1, pH 7 (binding buffer). For every 10 ml of crude extract (protein 
concentration 15-17 mg/ml),  1 ml of packed heparin-Sepharose was used. 
After extensive washing, affinity columns were eluted stepwise with 1.1 and 
2.5 M NaCI in 10 mM Tris-HCl, pH 7. The 2.5 M salt eluate was immedi- 
ately concentrated down to 50-100/tl by centrifugation using microconcen- 
trators (Centricon-10; Amicon Corp., Danvers, MA). Aiiquots from these 
concentrates were used for protein determinations and immunoblotting. 
To quantitate the amount of bFGF present in tissue extracts more ac- 
curately, minimizing losses, another approach was used:  1-2 ml of extract 
was mixed with 50 ~tl of settled heparin-Sepharose beads in 0.6 M salt. Sus- 
pensions were vortexed softly several times over a period of 2 h at room 
temperature; heparin-Sepharose beads were allowed to settle, and the super- 
natant was removed carefully. After several washes with binding buffer, the 
beads were incubated for an additional 10 rain with 1 ml of 1.1 M  NaCI, 
and  the  resulting  supernatant  was  removed.  This  was  followed  by  two 
washes with 0.1 M NaCi in 10 mM Tris-HCI, pH 6.8. Packed beads were 
finally incubated with 150/tl of gel sample buffer (0.1 M Tris-HCl, pH 6.8, 
1% SDS, 10% glycerol, and 5% [vol/vol] beta-mercaptoethanol) and boiled 
for 5 rain. The whole suspension was loaded into one gel lane. Recombinant 
bFGF, treated similarly, was recovered fully from the heparin beads in the 
gel and migrated identically to untreated bFGE 
Quantitation of bFGF in Cardiac Extracts 
Autoradiograms  from the Western blots  were  scanned by  densitometry. 
Recombinant bFGF was included in all the runs (1-20 ng/lane) and was used 
for the construction of standard curves, which were linear within the 1-10- 
ng/lane range. An estimate of the bFGF content of each sample was ob- 
tained, provided its scan fell within the standard curve. 
Immunological Reagents 
Rabbit  antiserum  against  the  [l-24]NH2-terminal  peptide  from  bovine 
brain bFGF (146 amino acids) was prepared as follows: 2 mg of the peptide 
(Bachem, Inc., Torrance, CA) was conjugated to 0.5 mg of keyhole limpet 
hemocyanin  with  1-ethyl-3-(3'-dimethylamino-propyl)  carbodiimide-HCI 
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Figure 1. Stimulation of DNA synthesis by cardiac extracts (chicken, 
rat, sheep, and bovine) in chicken skeletal myoblasts (SMs) after 24 h 
in culture. Shaded and unshaded columns represent ventricular and 
atrial extracts, respectively. The broken line shows the level of thy- 
midine incorporation in control cultures (no extract added). Values 
shown represent the mean of six determinations with the standard 
deviation indicated as a  vertical line. 
(Calbiochem-Behring Corp.) as described (40). Twa thirds of the resulting 
conjugate was mixed with Freund's complete adjuvant and used ~  immunize 
three rabbits by intradermal injections; the remaining third was mixed with 
incomplete adjuvant and used for booster injections 3 and 6 wk after the 
first. Rabbits were killed and immune sera collected 7  wk after the first 
injection. Purified anti-[1-24]bFGF IgGs were obtained by affinity chroma- 
tography: 4 mg of the peptide was conjugated to CNBr-activated Sepharose- 
4B (1.5 ml bed volume) according to the manufacturer's instructions (Phar- 
macia Fine Chemicals). Immune serum (1 ml), diluted with 10 ml of 0.5 M 
NaCI  in PBS, was repeatedly absorbed to the column. Specifically bound 
IgGs were eluted with 4  M  of MgCI2,  dialyzed in  PBS,  and  s~red at 
-70°C in the presence of 10%  (vol/vol) glycerol. Fluorescein-conjugated 
(FITC) donkey anti-rabbit lgGs were purchased from Amersham Corp., 
and rhodamine X-conjuga~l (XRITC) sheep anti-mouse IgGs were from 
Cooper Biomedical, Inc. (Malvern PA). Purified monoclonal mouse lgGs, 
recognizing striated muscle myosin, were a generous gift from Dr. R. Zak 
(University of Illinois, Chicago, IL). 
Immunofluorescence Microscopy 
Cardiac tissue was frozen in a dry ice/ethanol bath and used immediately 
for cryosectioning. Longitudinal or transverse sections 7 t~m thick were rou- 
tinely obtained using a cryostat (1720; E. Leitz, Inc., Wetzlar,  FRG). Sec- 
tions were collected on gelatin-coated slides. They were incubated with the 
anti-[1-24]bFGF (1-5/xg/ml) with or without antimyosin IgGs (at 2 #g/ml) 
in i% (wt/vol) BSA-PBS overnight at 4°C. After washing the sections with 
cold PBS, they were incubated with fluorescein-conjugated anti-rabbit IgGs 
and rhodamine X-conjugated anti-mouse lgGs at !:20 to 1:30 dilutions for 
1 h at 4°C. To reduce background reactivity, the anti-rabbit IgGs were usu- 
ally preabsorbed with heat-inactivated horse serum. After extensive wash- 
ing with cold PBS, sections were fixed in cold 95%  ethanol for 10 min, 
washed with PBS, and immersed for 30 s in 10/zg/ml of Hoechst Dye 33342 
(Calbiochem-Behring Corp.). Washed sections were mounted with glyc- 
erol/PBS (9:1),  sealed with colorless nail varnish, and stored at  -20°C 
until observation. A microscope (Diaphot; Nikon Inc., Garden City, NY) 
equipped with epifluorescence optics was used for observation and micro- 
photography of the sections. 
To test for nonspecific fluorescence the following controls were used: (a) 
nonimmune, purified rabbit IgGs (Sigma Chemical Co.) at identical dilu- 
tions with the immune IgGs (1-10/~g/ml); (b) immune IgGs after passage 
through a [1-24]bFGF-Sepharose affinity column; and (c) immune lgGs (10 
~g/ml) incubated with recombinant bovine bFGF (10 #g/ml) for 4 h at 4°C 
in  the presence of 1%  BSA-PBS and passaged through a  small heparin- 
Sepharose column (0.1 ml column bed volume for every 200/zl of incubation 
mixture). All controls used gave comparable results. A fluorescent image 
was considered to be bFGF-specific when it was obtained with the [1-24]bFGF- 
specific lgGs but not with any of the above mentioned controls. When im- 
mune lgGs were passaged through a keyhole limpet hemocyanin-Sepharose 
affinity column, or through a heparin-Sepharose column, they retained the 
same reactivity as nonpassaged immune IgGs. 
Results 
Mitogenicity of Cardiac Extracts 
Extraction of cardiac tissue with 2 vol of MEM (over tissue 
weight) resulted in ~1.5 vol of extract with a protein concen- 
tration of 15-17 mg/ml. MEM was used so that extracts could 
be tested immediately for biological activity on cells in vitro. 
Representative results are shown in Fig.  1,  where extracts 
have been tested at a final concentration of 0.5 mg/ml. DNA 
synthesis as measured by [3H]thymidine incorporation was 
increased two- to fourfold in the presence of extracts com- 
pared with untreated controls. The apparent concentration of 
mitogenic activity is higher in the atrial extracts (compared 
with ventricular ones) in all species tested (chicken, rat, bo- 
vine, and sheep). Furthermore, extracts from chicken hearts 
appear to have more mitogenic activity overall than any of 
the mammalian extracts (Fig.  1). Actual levels of stimulation 
obtained varied  somewhat between preparations;  speed of 
extraction and short-term storage result in better reproduci- 
bility and more active preparations, especially for the atrial 
extracts. Rat tissue extracts were very susceptible to activity 
losses and they were used immediately after preparation. 
The effect of cardiac extracts on myoblast differentiation 
was examined.  Stimulation of proliferation in combination 
with inhibition of terminal differentiation of myoblasts would 
most likely reflect the presence of bFGF-like activity. Differ- 
entiation (presence of multinucleated myotubes) was assessed 
by determination of fusion index. A single addition of cardiac 
extracts was made at the time of plating at a final concentra- 
tion of 0.5 mg/ml.  Results are summarized in Table I: after 
2.5 d, control cultures are differentiated, but all cultures in 
the presence of cardiac extracts are still proliferating. Fig. 2 
shows charactersfic results obtained in the presence of chicken 
extracts  after  4  d;  mammalian extracts produced identical 
results.  In the presence of atrial extracts,  cultures are still 
dominated by proliferating cells, while cultures treated with 
ventricular extracts are differentiated (Fig. 2 a and Table I). 
When ventricular extracts are supplemented with bFGF (10 
ng/ml) their effect is similar to that of the unsupplemented 
atrial extracts (Fig. 2, a  and c, and Table I). In contrast, if 
Table L  The Effect of Chicken Cardiac Extracts on 
Skeletal Muscle Differentiation  in Vitro* 
Fusion index (day after 
addition  of extract) 
Additions  2.5  4  6 
None (controls)  60  75  62 
Atrial extract  12  15  74 
Ventricular extract  27  80  70 
Ventricular extract 
+  bFGF (10 ng/ml)  15  15  70 
Ventricular extract 
+  IGF I  (20 ng/ml)  40  85  76 
* Extracts were added to the cells once at time of plating at a final concentra- 
tion of 0.5 mg/ml. Fusion index =  (nuclei  inside myotubes/total  number of 
nuclei)  x  100; each value represents an average of four determinations (each 
determination  varied by no more than 15% from the value  shown). 
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in the presence of chicken cardiac extracts (final concentration of 
0.3 mg/ml), with or without added growth factors, for 4 d. Cultures 
are fixed and stained with eosin and hematoxylin. Cultures grown 
with (a) atrial extract; (b) ventricular extract; (c) ventricular extract 
plus bFGF (10 ng/ml); and (d) ventricular extract plus IGF I (20 
ng/ml). Bar, 50 #m. 
IGF I is added with the ventricular extracts, muscle differen- 
tiation is not delayed (Fig.  2,  b  and d,  and Table I). If no 
more extract additions  are made,  all cultures are differen- 
tiated after 6 d  (Table I). 
A dose-dependent stimulation of myoblast [3H]thymidine 
incorporation by chicken atrial  and  ventricular extracts is 
shown in Fig. 3. Stimulation by the atrial extracts is higher 
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Figure 3. Dose-dependent stimulation of chicken skeletal myoblast 
DNA synthesis by chicken cardiac extracts after 24 h in culture. 
Squares and circles represent atrial and ventricular extracts, respec- 
tively. (Insert) Stimulation of chicken skeletal myoblast DNA syn- 
thesis (y-axis) by added bFGF (x-axis) in the presence of 0.5 mg/ml 
atrial (squares)  or ventricular extract (circles). Values shown repre- 
sent the mean of six determinations with the standard deviation in- 
dicated as a vertical line. 
Table II.  The Effect of  the 2.5 M Heparin Column 
Eluates from Cardiac Tissue Extracts on Rabbit Fetal 
Chondrocyte DNA Synthesis 
[3H]Thymidine incorporation 
Additions  by rabbit fetal chondrocytes 
cpm 
None  2,400 (200) 
bFGF (0.5 ng/ml)  4,600 (350) 
bFGF (2 ng/ml)  4,500 (450) 
Bovine A*  4,800 (500) 
Bovine V*  5,700 (550) 
Rat A  ND 
Rat V*  5,700 (600) 
Sheep A  ND 
Sheep V*  5,900 (600) 
Chick A*  5,400 (450) 
Chick V*  5,200 (550) 
A and V, 2.5 M salt eluate from  atrial and ventricular  extracts, respectively. 
(*) Final concentration of 10 ng/ml. Values shown represent an average  of six 
determinations with standard deviation from  the mean shown in parentheses. 
high extract concentrations, the difference in biological ac- 
tivity lessens (Fig.  3).  Both atrial and ventricular extracts 
were  supplemented  with  bFGF  and  tested  for  activity.  5 
ng/ml of bFGF induced a small (8%) increase in atrial, but 
a  sizeable (33 %) increase in ventricular mitogenicity (Fig. 
3, insert).  At 10 ng/ml of added bFGF, both types of extracts 
exhibit  identical  activities,  slightly  lower than  those  at  5 
ng/ml of added bFGF; we have previously seen this slight de- 
crease at bFGF concentrations above those needed for satu- 
ration of the mitogenic response (26). 
Identification of bFGF in Cardiac Extracts 
We had found previously that cardiac extracts passed through 
heparin  columns  lose  their  mitogenic  activity  (23).  The 
heparin-bound  fraction from all extracts tested did indeed 
possess rnitogenic activity for rabbit fetal chondrocytes as 
demonstrated by the results shown in Table II. Pure bFGF 
induces stimulation of a  similar magnitude.  This,  together 
with evidence presented above, suggests strongly that bFGF 
is the peptide largely responsible for rnitogenicity of cardiac 
extracts and can account for the differences between atrial 
and ventricular activities.  Further indirect support for this 
claim comes from the use of TGF/g-neutralizing antibodies 
with the extracts (Table HI). The inhibitory action of pure hu- 
man TGF/3 on cells is cancelled by neutralizing antibodies. 
When these antibodies are included with the cardiac extracts 
there is no change of extract mitogenicity (Table HI), which 
strongly suggests that the difference between atrial and ven- 
tricular  extracts  is  not  caused by  TGF~-like components. 
However, the possibility that endogenous TGF/~-like reac- 
tivities do not recognize the neutralizing antibodies cannot 
be totally ruled out.  To obtain positive evidence for bFGF 
presence and quantity in our extracts, we prepared antibod- 
ies against the  [1-24]NH2-terminal peptide of bovine brain 
bFGF. Pure anti-[1-24]bFGF IgGs obtained by affinity chro- 
matography were tested for specificity in immunoblots con- 
raining pure recombinant bFGF, aFGF, and serum or total 
crude cardiac extract protein. Pure immune IgGs (assayed at 
20 ng/ml to 5/~g/ml) recognized only bFGE Similar results 
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on the Mitogenic Activity of Cardiac Extracts 
[3H]Thymidine incorporation 
Additions  by rabbit fetal chondrocytes 
cpm 
None  2,400 (200) 
TGFB (1  ng/ml)  1,700 (200) 
Anti-TGFB (50 txg/ml)  2,600 (300) 
Rat atrial extract*  4,500 (450) 
Rat ventricular extract*  3,700 (300) 
Rat atrial extract* + 
anti-TGF/~ (50/~g/ml)  4,100 (500) 
Rat ventricular  extract*  + 
anti-TGFB  (50 #g/ml)  3,500 (450) 
(.) Final concentration  of 0.25 mg/ml. Values shown represent an average of 
six determinations with standard deviation from the mean shown in paren- 
theses. 
were obtained  with  enzyme-linked immunoassay,  using  as 
antigens 50 ng/ml of pure, nondenatured bFGF, total serum, 
extract proteins, or keyhole limpet hemocyanin (50 #g/well). 
A  detailed characterization of the  [1-24]bFGF IgGs will be 
presented  elsewhere  (Kardami,  E.,  manuscript  in prepara- 
tion). We therefore consider the purified IgGs bFGF specific 
and, as such, they were used to identify bFGF-like peptides 
in the heparin-bound fractions. A  silver-stained gel of some 
of these fractions is shown in Fig. 4  a,  where an  18,000-D 
band,  comigrating  with  pure  bFGF,  is  clearly detected  in 
atrial and ventricular heparin-binding fractions from chick- 
en and cow (Fig.  4  a,  lanes c-f).  This band is recognized 
by the anti-[1-24]bFGF IgGs in all cardiac fractions tested 
(Fig.  4  b  [chicken,  lanes  c  and d;  cow,  lanes  a  and b];  c 
[chicken, lanes a and b; sheep, lanes c and dl; and d  [chick- 
en, lanes b and c; rat lanes d and e]). A lower molecular mass 
(~I4,000-D)  heparin-binding  peptide  seen  in  the  silver- 
stained fractions and which may represent a truncated bFGF, 
as well as some larger peptides (Fig. 4 a), is not recognized 
by the antibodies.  In all  instances,  atrial  fractions contain 
more of the immunoreactive 18,000-D peptide (Fig. 4, a-d). 
This is illustrated clearly in Fig. 4 b, where the total heparin- 
binding fraction from 1 ml of chicken atrial (lane c) and ven- 
tricular  (lane d) extract is shown which was obtained with 
a  minimum of preparative  losses (see Materials  and Meth- 
ods). The lowest amount of immunoreactive bFGF was seen 
in the rat extracts (Fig. 4 d, lanes d and e). Rat extracts were 
particularly sensitive to loss of biological activity upon han- 
dling,  presumably due to degradation,  and this may be the 
reason for the low levels of bFGF detected by the antibodies. 
Figure 4.  Identification  of bFGF in cardiac extracts  (chicken,  rat,  sheep,  and bovine;  protein content =  15 mg/ml). (a) Silver-stained  gel 
with (lane a) 20 ng of recombinant bFGF; (lane b) relative molecular mass markers; and (lanes c-h) heparin-bound, 2 M salt eluates from 
cardiac tissue extracts.  Eluate  from 3.2 ml of chicken atrial  extract contained '~50 ng protein  (lane c); 6.4 ml of chicken ventricle  extract 
contained  100 ng protein (lane d);  13 ml of bovine atria  extract  contained  150 ng protein  (lane  e);  17 ml of bovine ventricle  contained 
100 ng protein (lane f); 5 ml of rat atria contained 30 ng protein  (lane g); and 10 ml of rat ventricle  extracts contained 50 ng protein  (lane 
h).  (b-d) Autoradiograms of Western blots  incubated  with anti-[1-24]bFGF antibodies.  (b) Heparin-bound, 2 M salt eluate from extracts 
from bovine atria  (13 ml; lane a) and ventricle  (17 ml; lane b); heparin-bound fraction from 1 ml of chicken atria  (lane c) and ventricle 
(lane d); and recombinant bFGF (4 ng; lane e).  (c) Heparin-bound eluate  from extracts  of chicken ventricles  (10 ml; lane a) and  atria 
(5 ml; lane b) and sheep ventricle  (10 ml; lane c) and atria  (5 ml; lane d).  (d) Heparin-bound eluate  from extracts  of chicken ventricle 
(15 ml; lane b) and atria (10 ml; lane c); rat ventricle  (10 ml; lane d) and atria (7 ml; lane e); and 5 and  10 ng recombinant bFGF (lanes 
a  and f,  respectively). 
Kardami and Fandrich Basic Fibroblast Growth Factor in the Heart  1869 Table IV. Immunoreactive bFGF Concentration  well with the result obtained from bFGF quantitation in ex- 
in Heart Tissues  tracts. 
Tissue  Amount bFGF per extracted tissue 
ng/8 
Chicken atria  4.6 
Chicken ventricles  1.4 
Bovine atria  I. 1 
Bovine ventricle  0.4 
Sheep atria  1.4 
Sheep ventricle  0.5 
Rat atria  0.3 
Rat ventricles  O. 1 
Values shown  represent the  mean from  three determinations (each  from  a 
different preparation).  Each determination  did not vary by more than 20% from 
the values shown. 
Fractions from two different chicken preparations are shown 
in Fig. 4, c and d. A higher molecular mass (23,000-D) pep- 
tide, revealed by its reactivity with the antibodies, is always 
present in the ventricular but has not been seen in the atrial 
fractions. Storage did not have any detectable effect on its 
quantity  (our  unpublished  observations).  This  peptide  is 
considered to be bFGF-like because it binds heparin with 
high affinity and reacts with the anti-bFGF antibodies. It has 
been observed in all  chicken ventricular preparations ob- 
tained so far. An additional bFGF-like peptide of ~17,000 D 
is also seen in ventricular but not atrial preparations from 
sheep hearts (Fig. 4 c, lanes c and d). 
We have attempted to quantitate the  18,000-D  bFGF-like 
peptides  present in  heart extracts by densitometry of au- 
toradiograms obtained from immunoblots reacted with iodi- 
nated protein A (see Materials and Methods). We assumed 
that bFGF-like peptides  from various tissues  and  species 
contain the same number of immunoreactive epitopes since 
bFGF is a highly conserved molecule and chicken bFGF is 
reported to have same amino acid composition as bovine 
bFGF (18). In addition, the amount of the 18,000-D heparin- 
bound peptide from all cardiac extracts examined, as seen in 
silver-stained gels (Fig. 4 a  and our unpublished observa- 
tions), agreed very well with the amount estimated by im- 
munoreaction. As seen in Table IV, atrial extracts contain at 
least twice as much immunoreactive 18,000-D bFGF as ven- 
tricular,  and  avian  extracts have at  least  three  times  the 
amount of mammalian extracts.  It is expected that values 
shown in Table IV represent a lower estimate of the actual 
amount of bFGF present in cardiac compartments because 
of preparative losses and probable degradation during han- 
dling. It is also conceivable that active bFGF-like peptides 
may be present in different tissues that are not recognized by 
our antibodies. This is unlikely since bFGF is highly con- 
served (18-20) and biological activity data (Fig. 1) agree well 
with the approximate quantitation obtained from the immu- 
noblots. 
It is possible that the observed differences in bFGF con- 
centration  in  the  extracts  reflect  real  differences  in  the 
amount of bFGF present in vivo in various tissues. However, 
differences in tissue "extractability" could also account for 
differences in the amount of bFGF in the extracts and cannot 
be ruled out at this point; as will be shown in the following 
section, in at least one case (bovine atria vs. bovine ventri- 
cle), visualization of bFGF-like reactivities in vivo agrees 
Localization of  bFGF in Bovine Cardiac Tissue 
Sections by Indirect Immunofluorescence 
Our  anti-[l-24]bFGF  antibodies  are  highly  specific  for 
bFGF in immunoblots and enzyme-linked immunoassays. 
They recognize a part of the bFGF molecule at the edge of 
one of the heparin-binding domains (6). These IgGs there- 
fore might bind bFGF even if it is "trapped" by heparin-rich 
areas  in  its  physiological  environment.  Anti-[l-24]bFGF 
IgGs  may  recognize common  sequences  present  in  non- 
bFGF peptides. This is not very likely since they do not react 
with any other peptide in crude bovine tissue extracts. When 
pure IgGs are absorbed with native bFGF they lose their re- 
activity completely. Staining observed by indirect immuno- 
fluorescence is therefore considered bFGF specific. 
We investigated the immunoreactivity of bovine atrial and 
ventricular  sections,  focusing primarily  on  cardiac  myo- 
cytes. Cardiac muscle was identified by simultaneous label- 
ing of sections with antibodies specific for striated muscle 
myosin; nuclei were identified by staining with the fluores- 
cent dye Hoechst 33342. Fig. 5, a-c, shows a characteristic 
triple-stained section from ventricular tissue and is used to 
illustrate the fact that muscle nuclei bind the anti-[l-24]bFGF 
IgGs (Fig. 5, a-c, shows bFGF immunofluorescence, myosin 
immunofluorescence, and nuclear fluorescence, respective- 
ly). Triple fluorescence staining was used to ensure that the 
bFGF immunoreactive nuclei belonged to muscle as well as 
nonmuscle cells. Muscle nuclei appeared to accumulate bFGF 
in association with their membranes, as seen most clearly in 
Fig. 5 d. They were recognized by the antibodies in both ven- 
tricular and atrial sections (Fig. 5, a, d-f, h, and i). Atrial 
myocytes seem to accumulate bFGF pericellularly to a greater 
extent than ventricular myocytes (Fig.  5, compare a  and d 
with e andfand h with i). Longitudinal sections were also 
tested for bFGF immunoreactivity: as shown in Fig. 6, a, b, 
e, andf the intercalated disc area from both atrial and ven- 
tricular  fibers exhibits  very bright  fluorescence.  Sections 
treated  with  non-bFGF-specific IgGs  (see  Materials  and 
Methods), at concentrations similar to the specific antibod- 
ies (2-10 #g/ml), always presented a very weak fluorescence 
of the same region (see control sections from two different 
experiments in  Fig.  6,  c  and d).  Immunoreactive muscle 
nuclei can be also seen in longitudinal sections (Fig.  6,  e 
and f). 
Blood vessels stain brightly (Fig. 5 e) in all their layers. 
Single cells near muscle fibers (Fig. 7 a; Fig. 6f; Fig. 5 e) 
show pericellular bFGF accumulation.  In  addition,  small 
populations of cells (groups of two to six) in the interstitial 
space show particularly bright immunostaining as seen in 
Fig. 7 c; muscle nuclear immunostaining, although present, 
is not discerned in this picture which has been exposed for 
the brightness of the group of nonmuscle cells shown. Capil- 
laries (endothelial cells) between muscle fibers also appear 
to accumulate bFGF (Fig. 5, h and i, large arrowheads). 
In  sections from ventricular myocardium nearest to the 
subepicardial layer we consistently (preparations from four 
different bovine hearts) observe a structure which stains bril- 
liantly with the [I-24]bFGF antibodies (Fig. 8). This struc- 
ture is found encased between muscle fibers (Fig. 8, a  and 
d),  does not react with myosin antibodies (not shown),  is 
The Journal of Cell Biology, Volume 109,  1989  1870 Figure 5.  Localization of bFGF (a, d-f, h,  and i)  in muscle and nonmuscle cells in sections of bovine ventricular (a-d, g, and h) and 
atrial (e, f, and i) tissue at high (a-g) and low magnification.  Direction of sectioning was at approximately right angles to the long axis 
of muscle fibers. Double immunofluorescence stain for bFGF (a), muscle myosin (c), and Hoechst 33342 nuclear stain (b) identifies muscle 
fibers, nonmuscle cells, and nuclei and shows nuclear localization of bFGE Staining with non-bFGF-specific rabbit IgGs is shown in g 
(overexposed photograph). Perinuclear accumulation of bFGF is seen clearly in d. Pericellular staining is shown in e,f, and i. Small arrow- 
heads mark muscle nuclei, while large arrowheads point at nonmuscle, bFGF-specific staining.  Compare bFGF distribution between atria 
and ventricles in h and i; Bars:  (a-g) 6 ttm; (h and i)  10 #m. 
roughly egg shaped,  has a  width  of 60-100/zm  and  length 
of ~  200  #m,  binds hematoxylin with high  affinity (Fig.  8 
c), and contains many nuclei (Fig.  8 b). One to two of these 
structures are encountered  per square centimeter of subepi- 
cardial tissue.  The identity of this structure is currently un- 
der  investigation. 
Discussion 
Because bFGF has been strongly implicated with tissue re- 
pair in vivo (5,  11,  17-20),  we examined cardiac atrial  and 
ventricular  extracts  for  bFGF-like  activities  as  part  of an 
effort to understand differences in regenerative properties of 
cardiomyocytes  (47).  Rabbit  fetal  chondrocytes  and  em- 
bryonic avian myoblasts,  which are both highly  responsive 
to bFGF (25-27, 44),  were used in indirect biological activ- 
ity assays. In both instances, mitogenic stimulation was more 
pronounced in the presence of atrial extracts from all animals 
tested.  In  addition,  atrial  extracts  delayed  skeletal  muscle 
differentiation  in  a  manner  identical  to that of pure bFGF 
(25). These data suggested that differences in extract activity 
could be accounted for by differences in bFGF content.  The 
activity  of cardiac  extracts  remained  unaffected  by TGF~- 
neutralizing  antibodies,  which suggests that if this  factor is 
present it is at concentrations too low to have an effect on ex- 
tract biological activity.  IGFs are also found in heart tissue 
(12).  Heparin absorption of the extracts nevertheless results 
in an almost complete loss of mitogenicity extracts (23); this 
implicates a heparin-binding  mitogen rather than an IGF ac- 
tivity. In addition, IGFs stimulate skeletal muscle differentia- 
Kardami  and Fandrich Basic Fibroblast Growth Factor in the Heart  1871 Figure 6. Localization of bFGF-like reactivities (a, b, e, and f) in 
cardiac muscle intercalated disc region (a, b, e, and f), cardiac 
muscle nuclei (e and f), blood vessels (e), and interstitial cells (f). 
Sections  were  cut  parallel  to  the  long  axis  of the  fibers. Im- 
munofluoresence stain for bFGF in sections from bovine ventricles 
(a and c-f) and atria (b). Control stain shown in c and d (nonim- 
mune rabbit IgGs and bovine whole bFGF-absorbed immune IgGs, 
respectively). ID, intercalated discs; M, muscle nuclei; and N, non- 
muscle cell.  Fluorescein-conjugated IgGs in d-f were not prein- 
cubated with heat-inactivated horse serum.  Bars: (a-c)  10/~m; 
(d-f) 50 #m. 
tion (14) so, if they are present in our extracts, their effect 
is masked by bFGF-like activities that have an apparently op- 
posite effect. 
Another heparin-binding factor that coexists with bFGF in 
some tissues  is aFGF (19).  Polyclonal aFGF-specific anti- 
bodies show no reactivity with the heparin-bound cardiac 
fractions eluting  at  1.1  M  salt  (our  unpublished  observa- 
tions). We therefore conclude that the major mitogen in our 
cardiac tissue extracts is a bFGF-like activity, being more 
abundant in atrial extracts. Direct evidence for this claim was 
obtained by fractionating extracts by heparin affinity chro- 
matography and testing the 2.5 M salt eluates for biological 
activity and reactivity with anti-bFGF IgGs.  An immuno- 
reactive 18,000-D  peptide was identified in all cases, comi- 
grating with recombinant bovine bFGE The amount of this 
peptide was always higher in the atrial extracts, confirming 
results  from biological assays.  It is therefore tempting to 
correlate higher concentrations of  bFGF in the atria with the 
proliferative and regenerative properties of atrial myocytes. 
Recent findings by us and others show that bFGF does stimu- 
late embryonic or adult cardiomyocyte  DNA synthesis as well 
as embryonic cardiomyocyte  proliferation in vitro (9, 21, 22). 
Chicken extracts from either ventricles or atria had the 
highest concentration of immunoreactive bFGF among the 
species examined. The 23,000-D bFGF-like peptide in chick 
ventricular extracts may represent a  precursor of the pre- 
dominating 18,000-D form. Its presence in small amounts in 
ventricular but not atrial extracts could be explained by in- 
creased proteolytic activity in the atrial extracts. The NH2- 
terminal portion of bFGF is very susceptible to limited pro- 
teolysis by naturally occurring proteases (29) and higher mo- 
lecular mass bFGF peptides do exist in embryonic tissue that 
can produce the 18,000-D form after digestion (32). What- 
ever the relationship between the 23,000- and 18,000-D pep- 
tides may be, it is interesting that the 23,000-D peptide is 
present in embryonic atrial extracts and it increases in quan- 
tity in embryonic ventricular extracts (Kardami, E., manu- 
script in preparation). 
An important question that has been addressed indirectly 
so far, concerns the exact localization of bFGF within tis- 
sues, which may provide a clue for its function in vivo. The 
high affinity of this peptide for heparin and heparan-sulfate 
(17), its accumulation in tissues rich in extracellular matrix 
(4,  5,  25),  and the relative ease for its extraction suggest 
strongly that bFGF is an extracellular matrix component. 
Immunofluorescence of cardiac tissue sections supports this 
notion, particularly for the atrial myocardium. Atrial myo- 
fibers appear surrounded by bFGF-rich endomysium. Ven- 
tricular myofibers axe much more compact and accumulate 
less  bFGF  pericellularly.  This difference, in  combination 
with the smaller size of atrial fibers (more intercalated discs 
and more nuclei per unit mass), is most likely contributing 
to higher bFGF concentrations in  the atrial  extracts.  The 
significance of bFGF accumulation around atrial myofibers 
is as yet unknown. It is tempting to speculate that it may have 
an effect on atrial cell proliferative properties. 
The presence of bFGF inside atrial and ventricular muscle 
ceils and in association with the nuclear membrane is  in- 
triguing since it suggests that bFGF is synthesized by the 
myocytes. Many cell types that are responsive to bFGF syn- 
thesize this peptide in culture (20, 45), implying an autocrine 
mode of growth regulation. The source(s) of bFGF accumu- 
lated in vivo is nevertheless unknown. Since tissues with a 
high degree of vascularization also contain high  levels of 
bFGF, endothelial cells are believed to be the source of this 
factor (18, 20). Our data suggest that other cell types, such 
as cardiac myocytes, are candidates for bFGF production in 
vivo. This is an attractive notion since cardiac muscle differ- 
entiates very early during embryonic development, before 
any vessels are formed. Release of bFGF activities by the 
myocytes could be a trigger for formation of capillaries and 
vessels in the heart, as well as for promoting cardiac innerva- 
tion (39, 46). 
The presence of bFGF-like components in the intercalated 
disc  areas  of the  myocytes suggests  an  involvement with 
cell-cell recognition, attachment, and communication. This 
The Journal of Cell Biology, Volume  109, 1989  1872 Figure 7. bFGF in interstitial ceils (a and c). Double staining for bFGF (a and c; immunofluorescence) and nuclei (b and d; Hoechst 33342) 
in longitudinal sections from bovine ventricles. M, muscle nuclei, N, nonmuscle cells. Bar, 20 #m. 
has been already predicted from the amino acid sequence of 
bFGF which contains cell recognition sequences (13). In ad- 
dition, bFGF was shown to influence cell-substratum adhe- 
sion in a  sympathetic nerve cell line (39). 
Our observations have been focused mainly on striated 
muscle cells in the heart, bFGF nevertheless was accumu- 
lated by other cell types. Blood vessels show accumulation 
in  all  their  layers,  in  association  most  likely  with  their 
heparan-sulfate-rich extracellular matrix (4).  Certain con- 
nective tissue cells also stain very brightly with the anti-bFGF 
IgGs. This is not unexpected since connective tissue contains 
mast cells, macrophages, or fibroblasts, all of which proba- 
bly contain bFGF in vivo. 
Could  bFGF  be  recruited  in  inducing  cardiomyocyte 
regeneration? It has been speculated that degradation of ex- 
tracellular matrix by enzymes released through the immune 
response would liberate bFGF which could then stimulate 
cell proliferation within the available space (4). Nonmuscle 
ceils would probably respond faster and no significant myo- 
cyte regeneration would occur before damaged tissue was 
replaced by scar tissue. If, however, the action of bFGF on 
nonmuscle cells could be slowed and that on muscle cells 
promoted to the point of actual cell division, this might result 
in effective muscle regeneration or at least reduction of scar- 
ring. There is evidence that regulation of proliferation differs 
depending  on  cell  type.  TGF/$, for  example,  stimulates 
fibroblast proliferation while it cancels the action of bFGF 
on endothelial cells, skeletal myoblasts (14, 43), and cardiac 
neonatal myocytes (22, 23). Since TGF~, as well as bFGF, 
is present in the heart (35), effective inhibition of its action 
may be a way of stimulating myocyte, while delaying fibro- 
blast, proliferation. Further studies on the control of growth 
Figure 8.  bFGF in an unidentified structure in the bovine ventricle (a and b). Double fluorescence staining for bFGF (a) and nuclei (b) 
in longitudinal section. Histochemical staining (eosin-hematoxylin) of similar structure (c) shows strong affinity for hematoxylin. Bars: (a 
and b) 50/~m;  (c) 50/~m. 
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cell types will be of invaluable assistance in understanding 
the processes involved in tissue regeneration. 
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